You Position: Home > Paper

Report on recent treatment of Hodgkin's lymphoma in the 53rd annual meeting of American Society of Hematology

( views:506, downloads:228 )
Author:
No author available
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
2
DOI:
10.3760/cma.j.issn.1009-9921.2012.02.003
Key Word:
霍奇金淋巴瘤;移植;美国血液学会年会;Hodgkin's lymphoma;Transplant;American Society of Hematology annual meeting

Abstract: Hodgkin's lymphoma (HL) is a highly curable malignancy for most patients during the recent decades. Frontline treatment is generally ABVD alone or in combination with other chemotherapy regimens or radiation. To achieve a higher control of disease, ABVD chemotherapy has been challenged by more intensive treatments, such as Stanford V and BEACOPP regimen. In the 53rd ASH annual meeting,ABVD is still widely accepted as standard regimen for HL, even in elderly people or patients with HIV infection. Relapsed or refractory HL is a challenging problem for clinician, and high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT) is the preferred treatment for chemoresistant patients.Many novel treatment strategies were explored for these patients.Positron emission tomography (PET) scanning provides important prognostic information in patients with HL receiving chemotherapy or pre/posttransplant,but the utility of long term surveillance radiological studies is not recommended in the meeting.

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn